GHK CU, usually written GHK-Cu, is the copper(II) complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine. The peptide was first identified in human plasma, and it binds copper with high affinity to form a stable blue complex of roughly 404 Da. In the laboratory it is studied as a model copper-binding peptide, as a modulator of extracellular matrix synthesis and gene expression in cultured cells, and as a compound in redox and inflammation signalling experiments. This article covers its structure, mechanism, published research, applications and the analytical and handling requirements that determine data quality.
What is GHK CU?
GHK-Cu consists of a tripeptide, Gly-His-Lys, coordinated to a copper(II) ion in a 1:1 ratio. The free peptide has the formula C14H24N6O4 and a molecular weight of about 340 Da. Adding copper brings the complex to roughly 404 Da. In the complex, the metal is held by the N-terminal amino group of glycine, a deprotonated backbone amide nitrogen and the imidazole ring of histidine, which together form a stable square-planar arrangement. The lysine side chain does not bind the metal directly but contributes charge and influences solubility.
The molecule was described by Loren Pickart and Mary Thaler in 1973, who reported in Nature New Biology that a tripeptide fraction from human plasma albumin prolonged the survival of normal liver cells in culture and altered the growth of neoplastic liver cells. They later showed that the active factor binds copper and proposed that it may facilitate copper uptake into cells. The sequence is also present in the α2 chain of type I collagen, which led Maquart and colleagues in the 1980s to suggest that the peptide could be released during proteolytic breakdown of collagen and could act as a signal after tissue damage.
Related terms cause some confusion. GHK is the metal-free peptide, GHK-Cu is the copper complex, and cosmetic-industry names such as “copper tripeptide-1” refer to the same chemistry. These forms differ in colour, charge and redox behaviour, so a certificate of analysis should state which form was tested and how the copper content was measured.
Mechanism of action
No single receptor has been established for GHK-Cu, and the literature describes several overlapping mechanisms instead. The first is metal binding. The peptide holds copper(II) tightly yet can exchange it with other ligands, which led to the proposal that it works as a copper carrier that moves the metal between albumin and cells. Copper is a cofactor for enzymes involved in connective tissue cross-linking and antioxidant defence, including lysyl oxidase and superoxide dismutase, so changes in copper availability can influence matrix and redox biology.
The second mechanism concerns gene expression. Pickart and Margolina analysed data from the Broad Institute’s Connectivity Map, a public library of transcriptional responses to small molecules, and reported that GHK altered the expression of a large share of human genes. At a cutoff of a 50% change, roughly 31% of genes were affected, with about 59% of those increased and 41% suppressed. The affected genes covered extracellular matrix components, protease and protease-inhibitor systems, and antioxidant and inflammatory pathways.
The third mechanism involves matrix remodelling in cell culture. Studies in fibroblast and keratinocyte cultures have reported increased synthesis of collagen, glycosaminoglycans and the proteoglycan decorin, together with changes in matrix metalloproteinase and tissue inhibitor (TIMP) expression. Work with GHK CU in macrophages has also pointed to effects on inflammatory signalling, including reduced activation of NF-κB p65 and p38 MAPK, along with lower reactive oxygen species and higher superoxide dismutase activity.
Researchers should interpret these findings with care. Most data come from cell cultures and rodent models at defined concentrations, and the copper in the complex can itself be redox-active, so controls that separate the effect of the peptide from that of copper alone, such as a copper salt control, are good practice.
What the research shows
Four sets of published work frame the field.
The first is the original isolation. Pickart and Thaler, in the 1973 paper noted above, reported that a tripeptide from human albumin influenced the growth of liver cells in culture, which was the first description of GHK as a plasma factor with biological activity in vitro. The study set the direction for later work on its copper binding.
The second is the work on matrix synthesis. Maquart and colleagues reported in 1988 in FEBS Letters that the GHK-copper complex stimulated collagen synthesis in fibroblast cultures. This paper is widely cited as the basis for the use of the peptide in connective-tissue and wound-repair models, where it serves as a positive control for matrix-protein induction.
The third is a mouse model of inflammation. Park and colleagues reported in Oncotarget in 2016 that, in LPS-stimulated RAW 264.7 macrophages, concentrations of 1 to 10 μM GHK-Cu reduced reactive oxygen species and raised superoxide dismutase activity, and lowered TNF-α and IL-6 through reduced NF-κB p65 and p38 MAPK signalling. In C57BL/6 mice, the authors administered 1 or 10 μg/g intraperitoneally every 24 hours for three days before intratracheal LPS, and reported lower lung histological injury scores and reduced inflammatory cell infiltration compared with LPS alone. The study is indexed on PubMed.
The fourth is the gene-expression analysis. Pickart and Margolina’s 2018 review in the International Journal of Molecular Sciences brought together Connectivity Map data with earlier cell-culture and animal findings, including studies of wound models in rats, and proposed that GHK acts as an injury-response signal that modulates multiple pathways. The review is a useful starting point for the primary literature and is indexed on PubMed. As with any review, readers should check the original papers, and the human data discussed in it fall outside the scope of this laboratory-focused article.
Research applications
The most common use is in fibroblast and keratinocyte culture, where GHK CU is applied at defined concentrations to study collagen, elastin, glycosaminoglycan and proteoglycan synthesis, and to follow changes in matrix metalloproteinase and TIMP expression. Typical readouts include ELISA, qPCR, western blot and hydroxyproline assays. Wound-model research is a second area, including scratch assays in monolayers and three-dimensional culture systems, where the peptide serves as a reference matrix-remodelling agent.
Inflammation and oxidative stress is a third area, with macrophage cultures and rodent models used to examine NF-κB and MAPK signalling, cytokine release and antioxidant enzyme activity. Metal biochemistry and analytical chemistry form a fourth. GHK-Cu is a well-studied model of a copper-binding peptide, used to examine coordination chemistry by UV-visible and EPR spectroscopy, to test competing chelators and to study ternary complexes with other biological ligands. Finally, formulation scientists study delivery of the complex in liposomes and other carriers in vitro, which depends on knowing the stability of the copper-peptide bond in different media.
Purity, storage and handling
Verification of a copper peptide needs more than the usual peptide checks. Reversed-phase HPLC gives peptide purity as percentage peak area, and it should be paired with mass spectrometry. In electrospray mass spectra the complex shows the characteristic isotope pattern of copper, in which ⁶³Cu and ⁶⁵Cu occur in a ratio of about 69:31, and this pattern helps separate the complex from free GHK. Copper content should be confirmed independently by ICP-OES, ICP-MS or a comparable elemental method, because a product sold as GHK-Cu may contain sub-stoichiometric copper or free copper salts. Net peptide content matters as well, since the powder also contains counter-ions and bound water.
Because degradation accelerates once reconstituted, batch-level HPLC verification matters more here than with more stable peptides. UK laboratories sourcing GHK CU should expect a batch-specific certificate of analysis, copper content data and lyophilised storage at -20°C, and anyone comparing the best peptides supplier uk options can apply the same documentation checks to any vendor.
A batch-specific certificate matters because the copper-to-peptide ratio, impurity profile and salt form can differ between production runs. The certificate should list the batch number, HPLC conditions and chromatogram, the observed mass with isotope pattern, the copper content and the test date. Endotoxin testing is advisable for cell-based work, and especially for the macrophage experiments described above, since lipopolysaccharide contamination would directly confound inflammation readouts.
Lyophilised material is generally stored at -20°C in a sealed, desiccated container, because the powder is hygroscopic. Vials should reach room temperature before opening to prevent condensation. After reconstitution, stability depends on the medium. Chelating components such as EDTA, and histidine-rich or other strongly copper-binding media, can strip or compete for the metal, and extremes of pH can dissociate the complex. Stock solutions are normally kept at 2-8°C for short periods and divided into single-use aliquots to avoid repeated freeze-thaw cycles, with compatibility confirmed for each assay medium. Exact stability windows should be taken from supplier data and verified in-house for critical work.
Light sensitivity is moderate. Copper complexes can undergo photochemical reactions and the histidine imidazole is susceptible to photo-oxidation, so amber vials or dark storage are advisable. Researchers should also remember that copper compounds are covered by COSHH risk assessment requirements and should be disposed of according to institutional rules on metal-containing waste.
Frequently asked questions
What is the difference between GHK and GHK-Cu?
GHK is the free tripeptide glycyl-L-histidyl-L-lysine, about 340 Da. GHK-Cu is its 1:1 complex with copper(II), about 404 Da. The metal changes colour, charge and redox behaviour, so the two are not interchangeable in assays, and a certificate should state which form was analysed.
Why is GHK-Cu blue?
The copper(II) complex absorbs weakly in the visible region near 600 nm, which gives the powder and its solutions a blue to violet tint. Colour is a rough sign that copper is bound, but it is not quantitative, so copper content should be confirmed by ICP or a similar elemental method.
How should lyophilised GHK-Cu be stored?
Lyophilised GHK-Cu is generally stored at -20°C in a sealed, desiccated container protected from light, and brought to room temperature before opening. Reconstituted solutions are usually kept at 2-8°C for short periods as single-use aliquots, with stability limits and buffer compatibility confirmed from batch documentation.
How are the purity and copper content of GHK-Cu verified?
Peptide purity is measured by reversed-phase HPLC, identity by mass spectrometry showing the copper isotope pattern, and copper content by elemental analysis such as ICP-OES or ICP-MS. A good certificate states peptide purity, the copper-to-peptide ratio, the salt form and the test date for the specific batch.
GHK CU is supplied for in-vitro laboratory research only. It is not for human or veterinary use, and it must not be administered to people or animals.